COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment
Fabio M. Pulcinelli(Sapienza University of Rome), Filippo Crea(Università Cattolica del Sacro Cuore), Luigi M. Biasucci(Agostino Gemelli University Polyclinic), Teresa Mattiello(Sapienza University of Rome), Giovanni Ghirlanda(Università Cattolica del Sacro Cuore), Dario Pitocco(Agostino Gemelli University Polyclinic), Giovanna Liuzzo(Agostino Gemelli University Polyclinic), Elisabetta Trifirò(Sapienza University of Rome), Angelo Di Leo(Hospital of Prato), Silvia Riondino(Sapienza University of Rome), Simona Giubilato(Università Cattolica del Sacro Cuore), Livia Di Renzo(Sapienza University of Rome)
Cited by 87
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
The Charcot Foot in Diabetes
|Diabetes Care|2011|558
Aspirin resistance: position paper of the Working Group on Aspirin Resistance
|Journal of Thrombosis and Haemostasis|2005|329